logo
U.S. cancer survivors grow to 18.6M; predicted to reach 22M by 2035

U.S. cancer survivors grow to 18.6M; predicted to reach 22M by 2035

UPI3 days ago

Breast cancer survivors march to the stage before the start of the Susan G. Komen Race for the Cure in St. Louis in 2018. A study published Friday estimated 18.6 million cancer survivors live in the United States, up from 18 million in 2022. The number is expected to rise past 22 million by 2035. File Photo by Bill Greenblatt/UPI | License Photo
ST. PAUL, Minn., May 30 (UPI) -- The number of cancer survivors living in the United States is continuing its steady increase, rising to an estimated at 18.6 million as of Jan. 1, according to a study published Friday by the American Cancer Society.
That number is projected to exceed 22 million by 2035, and is up from 18 million survivors in 2022, the authors found.
Friday's peer-reviewed study, published in the cancer society's CA: A Cancer Journal for Clinicians, also found that about half of those 18.6 million survivors were diagnosed within the past 10 years, and that nearly 4r out of 5 of them were 60 years old and older.
The latest figures continue a pattern in which the numbers of U.S. cancer survivors are increasing each year, partly as a result of the growth and aging of the population, but also due to improvements in early detection practices and breakthroughs in cancer treatments.
As in its previous estimates, the cancer society collaborated with the National Cancer Institute to tap data from a number of sources, including cancer registries kept by several federal agencies and the North American Association of Central Cancer Registries, as well as information from the U.S. Census Bureau.
Using that data, cancer society researchers determined that among men, the three most prevalent cancers are prostate (3.55 million survivors), melanoma of the skin (816,580), and colorectal (729,550).
Among women, the most common cancers were breast (4.3 million survivors), uterine corpus (945,540) and thyroid (859,890).
"The increase in cancer survivors in the United States is a testament to the tremendous progress made by cancer research efforts across multiple collaborative stakeholders resulting in improvements in prevention, risk reduction, early detection, diagnosis and treatment, said Dr. Crystal S. Denlinger, CEO of the National Comprehensive Cancer Network, an alliance of leading cancer centers.
"While this milestone should be celebrated, it is important to remember that cancer survivors have unique needs during and after treatment, and disparities still exist in the receipt of these life-saving advances," Denlinger said.
"Everyone should have access to high-quality cancer care as outlined in the latest evidence-based, expert consensus-driven guidelines. Through persistent research, broadened awareness, and unwavering access to guideline-concordant care, everyone has the potential to benefit from ongoing advances in cancer care and prevention."
Though the numbers of cancer survivors continue to increase, racial and socioeconomic disparities in treatment also remain readily apparent, the study found. For instance, Black people with Stage I or Stage II lung cancer were less likely to undergo surgery than their White counterparts by a 47% to 52% margin.
Dr. Nikita Sandeep Wagle, principal scientist within the Surveillance & Health Equity Science department of the cancer society and the study's lead author, told UPI she was surprised at "the extent to which treatment receipt differs in Black people compared to White people for some [other] cancers.
"For example, only 39% of Black people with early-stage rectal cancer received surgery, compared to 64% of their White counterparts," she said. "Addressing disparities requires improving access to high-quality cancer early-detection, treatment and survivorship resources by expanding access to affordable insurance coverage through public and private programs."
Meanwhile, perhaps the most encouraging aspect of the study relates to breast cancer. There, the statistics showed that the number of female breast cancer survivors is projected to jump from today's 4.3 million to 5.3 million by 2035 -- the largest expected survivor growth among the top 10 most prevalent cancers.
In 2022, the ACS estimated slightly more than 4 million women were living in the United States with a history of invasive breast cancer. That included more than 150,000 women living with metastatic breast cancer, three-fourth of whom originally were diagnosed with stage I-III disease.
One-third of female breast cancer survivors in 2022 were younger than 65, reflecting the relatively young median age at diagnosis of 63 years.
The projected increase to 5.3 million female breast cancer survivors and those living with breast cancer by 2035 "is a testament to progress in early detection and treatment of breast cancer -- but it's only part of the story," according to Susan G. Komen, the U.S.-based breast cancer advocacy organization.
While lauding the rising number of survivors, the group noted in a statement to UPI that every day this year, "we still lose about 117 people in the United States to this disease, and nearly 43,000 are expected to die from breast cancer in 2025 alone.
"Recent alarming trends also show breast cancer diagnoses are rising among younger women, with the disease being the leading cause of cancer death in women ages 20 to 49," they said.
Those survivors must also face complex challenges, ranging from loss of fertility and early menopause to fatigue, fear of recurrence and financial toxicity, "especially for those living with metastatic breast cancer.
"While survival rates have improved overall, significant disparities remain -- especially for Black women, who continue to face worse outcomes, as the report highlights," Susan G. Komen said. "Continued investment in research, equal access to care, and comprehensive support are essential to ensure everyone -- not just some -- has the chance to survive and thrive."
And, as the number of cancer survivors steadily rises, so does the need to keep them healthy, Wagle said.
"It is surprising that there are now as many as 18.6 million cancer survivors, meaning more people need health care access to monitor for cancer recurrence, new cancers and side effects of cancer treatment," she cautioned.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Two people rescued from small plane crash in Long Island Sound
Two people rescued from small plane crash in Long Island Sound

Yahoo

time7 hours ago

  • Yahoo

Two people rescued from small plane crash in Long Island Sound

June 1 (UPI) -- Crews rescued two people aboard a small plane that crashed into Long Island Sound Sunday near a Connecticut airport, according to the FAA and U.S. Coast Guard. The Piper PA-32 plane went down about 10:30 a.m. south of the Tweed New Haven Airport in New Haven, a statement from the FAA said. "The two persons onboard the aircraft were rescued and in stable condition," the Coast Guard said in a statement, according to ABC News. The Coast Guard dispatched a 45-foot New Haven-based rescue boat to the scene after the Sector Long Island Sound Command Center received notification of the incident from the air traffic control tower that the plane had gone down near the Thimble Islands close to Branford, Ct. The rescued passengers were taken to the Stony Creek Pier in Branford, the Coast Guard said. The FAA is investigating the incident.

FDA OKs new Moderna COVID-19 vaccine for 65+, others with conditions
FDA OKs new Moderna COVID-19 vaccine for 65+, others with conditions

UPI

time16 hours ago

  • UPI

FDA OKs new Moderna COVID-19 vaccine for 65+, others with conditions

A vial of the Moderna COVID-19 vaccine in the Meuhedet Clinic in Jerusalem on January 3, 2022. The FDA approved a new version of the vaccine on Friday. File photo by Debbie Hill/UPI | License Photo May 31 (UPI) -- The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened vaccine standards for the virus. The FDA announced Friday that mNEXSPIKE can be given to adults 65 and older and those 12 to 64 with at least one underlying condition that could put them at risk of severe infection. Recipients also must have been previously vaccinated for COVID-19. The company, headquartered in Cambridge, Mass., said Saturday it expects to have the vaccine available for the 2025-2026 respiratory virus season. Moderna also produces Spikevax for COVID-19, and mRESVIA for the respiratory syncytial virus, or RSV. "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," Stéphane Bancel, chief executive officer of Moderna, said. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health." STAT reported the next-generation COVID-19 vaccine uses a refined target to generate antibodies against the SARS-CoV-2 virus. The dose is one-fifth the doage used in Spikevax, the current vaccine. Moderna conducted a randomized, observer-blind Phase 3 clinical trial of approximately 11,400 participants aged 12 years and older to test the mRNA-1283. The primary efficacy was to demonstrate the vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared with Spikevax, Moderna's updated COVID-19 vaccine approved on Sept. 6, 2024. The new vaccine showed a 9.3% higher relative vaccine efficacy than the mRNA-1273 in individuals aged 12 years and older. It was 13.5% better in adults aged 65 and older. In the Phase 3 trial, the most common side effects were injection site pain, fatigue, headache and myalgia. The company said there is a very small chance that mNEXSPIKE could cause a severe allergic reaction, usually within a few minutes to 1 hour after getting a dose of mNEXSPIKE. Myocarditis, which is inflammation of the heart muscle, and pericarditis, which is inflammation of the lining outside the heart, have occurred in some people who have received mRNA COVID-19 vaccines, Moderna said. Of those with problems, they are among males12 through 24. The FDA has asked Moderna to conduct post-marketing studies to continue to evaluate the safety and effectiveness of the product. This includes a study on the outcomes of pregnant people and their babies when the vaccine was administered during pregnancy. The study is to be submitted by the end of 2032. Pfizer was the first COVID-19 vaccine to receive emergency approval in December 2020 and Moderna was followed one week later. The first COVID-19 cases were reported in the United States in January 2020. The FDA first granted Pfizer-BioNTech full COVID-19 approval for those 12 and older in August 2021 and Moderna in January 2022. They remain available under emergency use authorization for children as young as 6 months. On Friday, the Centers for Disease Control and Prevention said children without underlying health conditions "may receive" a COVID-19 vaccine, contradicting a directive by Health and Human Services Secretary Robert F. Kennedy Jr. earlier in the week. The CDC updated the childhood immunization schedule published late Thursday. Kennedy, who said the agency would stop recommending the shots for healthy children, noted the guidelines would be changed. The new schedule also requires health insurance companies, Medicare and Medicaid plans to continue to cover the vaccines for children. COVID-19 shots during pregnancy are listed as "No Guidance/Not Applicable," where they were previously recommended for all pregnant adults. Earlier this month, the FDA approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay. The agency approved the vaccine only for people 65 and older and those 12 and older with at least one underlying condition at a higher risk of severe illness. This week, HHS notified Moderna that it was canceling contracts worth $766 million to develop, test and license vaccines for flu subtypes that could trigger future pandemics, including the dangerous H5N1 bird flu virus. The first COVID-19 case was reported in the United States on Jan. 20, 2020. About 23% of U.S. adults are estimated to be up to date with the vaccine, according to the CDC through April. For children 6 months and up to 18, it is an estimated 13.%, the CDC reported.

New research presents promising findings on colorectal cancer treatment and prevention
New research presents promising findings on colorectal cancer treatment and prevention

Yahoo

time18 hours ago

  • Yahoo

New research presents promising findings on colorectal cancer treatment and prevention

Colorectal cancer is the second most common cause of cancer deaths in the United States, according to the American Cancer Society. This year, the organization estimates that more than 150,000 Americans will be diagnosed with it and nearly 53,000 will die from it. New studies presented at the annual meeting of the American Society of Clinical Oncology, or ASCO, in the last few days offer promising findings for both pharmaceutical and lifestyle interventions, including the impact of diet and exercise. Diagnoses of colorectal cancer have been decreasing overall for decades, the American Cancer Society says, thanks in large part to better screening. But case rates are rising among younger adults, and research estimates that colorectal cancer will become the leading cause of cancer death among adults ages 20 to 49 by 2030. Earlier research has suggested that regular exercise can improve survival rates for colorectal cancer patients, and a new study – published in the New England Journal of Medicine and presented at the ASCO conference on Sunday – confirmed those findings with robust clinical trial data. Between 2009 and 2024, researchers followed nearly 900 colon cancer patients who had completed chemotherapy – half of whom received an informational booklet that encouraged them to adopt a healthy lifestyle with good nutrition and exercise the other half of whom were also matched with a physical activity consultant for three years. They found that there was a 28% reduction in the risk of recurrence or new cancer for patients on the exercise program, with a five-year disease-free survival rate of 80% for the group with an exercise consultant compared with 74% for the group who just received the booklet. In other words, the exercise program was found to prevent 1 out of every 16 patients from developing recurrent or new cancer. 'That magnitude is comparable to – and in many cases exceeds – the magnitude of benefit offered by a lot of our very good standard cancer drugs,' said Dr. Christopher Booth, a professor of oncology with Queen's University and co-author of the new study. 'Exercise really should be considered an essential component of treatment of colon cancer.' Work is still being done to understand why exercise can help reduce the risk of cancer, but experts say that it may have something to do with the ways exercise helps reduce inflammation in the body. Another new study presented at the ASCO conference on Sunday found that anti-inflammatory diets also helped improve survival rates for people with stage 3 colon cancer. Patients who consumed more anti-inflammatory diets – including coffee, tea and vegetables such as leafy greens – and engaged in higher levels of physical activity had a 63% lower risk of death compared to patients who consumed the most inflammatory diets – including things like red meat, processed meat, refined grains and sugar-sweetened beverages – and engaged in lower levels of physical activity, the study found. 'Actively, as a field, we're learning about the role of the immune system in cancer development, and inflammation is an immune response,' said Dr. Sara Char, a clinical fellow in Hematology and Oncology at Dana-Farber Cancer Institute and lead author of the study, and the rise of colorectal cancer cases in younger people suggests it's a critical piece of the puzzle. 'When we look at the incidence of colon cancer in younger individuals … that really suggests to us that there is something in the environment – either in the foods we eat, our lifestyles, the chemicals that could be in our foods, all sorts of different things – that are outside of just genetics alone that could be driving these rates,' she said. 'So it is incredibly important for us, as a field, to be thinking about how our diet and lifestyle impacts not just our risk of developing this cancer, but then how people fare after it.' Both Booth and Char said that colorectal cancer patients are often seeking ways to proactively manage their risk. 'I think that's it's very empowering for patients,' Booth said. 'It's also achievable for patients. This is a commitment, but it's something that patients can achieve.' In his study, an 'exercise prescription' was developed based on each individual's starting point. Most people were able to reach their target increase if they went for a brisk walk for about an hour three or four days per week, Booth said. Lifestyle interventions like exercise and diet are also 'sustainable for health systems,' he said, but it's key that the system helps support patients in accessing the resources needed for behavioral interventions. Another new study showed promising results that might represent a new standard-of-care for certain patients with advanced colon cancer. On Friday, drugmaker Pfizer presented data on a colorectal cancer drug, Braftovi, used in combination with a standard chemotherapy and an antibody drug. During the trial, the drug combo was shown to double the length of time patients with an aggressive form of colorectal cancer lived with treatment: an average of 30 months compared with 15 months using currently available treatments. Braftovi targets a mutation in a specific protein that can lead to abnormal cell growth, and it's already approved by the US Food and Drug Administration to treat some forms of cancer. The study, which was funded by Pfizer, published Friday in the New England Journal of Medicine. 'It's a targeted cancer therapy that really depends on knowing what's driving patients' cancer,' Pfizer CEO Dr. Albert Bourla told CNN. These targeted therapies are one of the biggest advancements in cancer treatment over the past two decades, he said, and it's easy to diagnose whether cancer patients have the specific mutation that Braftovi can treat. The latest data on treatment for colorectal cancer a 'very, very important finding,' Bourla said, and the drugmaker plans to seek additional approval to add the new indication to the drug's label.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store